NYSE:CTLTCatalent Stock Price, Forecast & News

Catalent's stock was trading at $46.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CTLT shares have increased by 68.2% and is now trading at $77.47. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Catalent.

Catalent is scheduled to release its next quarterly earnings announcement on Tuesday, August 25th 2020. View our earnings forecast for Catalent.

Catalent Inc (NYSE:CTLT) posted its quarterly earnings results on Tuesday, May, 5th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.05. The company had revenue of $760.60 million for the quarter, compared to analysts' expectations of $696.10 million. Catalent had a return on equity of 14.58% and a net margin of 4.79%. Catalent's revenue was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.49 EPS. View Catalent's earnings history.

Catalent issued an update on its FY 2020 Pre-Market earnings guidance on Tuesday, May, 5th. The company provided earnings per share guidance of 1.79-1.93 for the period, compared to the Thomson Reuters consensus estimate of $1.78. The company issued revenue guidance of $2.87-2.95 billion, compared to the consensus revenue estimate of $2.83 billion.

7 analysts have issued twelve-month price objectives for Catalent's stock. Their forecasts range from $62.00 to $80.00. On average, they expect Catalent's share price to reach $72.33 in the next twelve months. This suggests that the stock has a possible downside of 6.6%. View analysts' price targets for Catalent.

Media headlines about CTLT stock have trended very negative on Monday, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Catalent earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Catalent.

Some companies that are related to Catalent include ASTELLAS PHARMA/ADR (ALPMY), Royalty Pharma (RPRX), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GMAB), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Beigene (BGNE), Sarepta Therapeutics (SRPT), Teva Pharmaceutical Industries (TEVA) and GALAPAGOS NV/S (GLPG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Alibaba Group (BABA), Energy Transfer LP Unit (ET), Pfizer (PFE), AT&T (T), Thermo Fisher Scientific (TMO), CVS Health (CVS), AbbVie (ABBV), Johnson & Johnson (JNJ) and Amgen (AMGN).

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent's stock is owned by a variety of institutional and retail investors. Top institutional investors include Mountain Pacific Investment Advisers Inc. ID (0.14%), Envestnet Asset Management Inc. (0.10%), Vigilant Capital Management LLC (0.09%), Louisiana State Employees Retirement System (0.03%), State of Alaska Department of Revenue (0.02%) and DNB Asset Management AS (0.01%). Company insiders that own Catalent stock include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, Donald E Morel, Jr, Gregory T Lucier, John J Greisch, John R Chiminski, Lance Miyamoto, Michael J Grippo, Peter L Buzy, Ricardo Pravda, Scott Gunther, Steven L Fasman and William Downie. View institutional ownership trends for Catalent.

CTLT stock was sold by a variety of institutional investors in the last quarter, including Vigilant Capital Management LLC, Mountain Pacific Investment Advisers Inc. ID, and Envestnet Asset Management Inc.. Company insiders that have sold Catalent company stock in the last year include Alessandro Maselli, Aristippos Gennadios, John R Chiminski, Michael J Grippo, Ricardo Pravda, and Scott Gunther. View insider buying and selling activity for Catalent.

CTLT stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, IFM Investors Pty Ltd, IBM Retirement Fund, Diversified Trust Co, Louisiana State Employees Retirement System, State of Alaska Department of Revenue, and Livforsakringsbolaget Skandia Omsesidigt. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, John J Greisch, and Peter L Buzy. View insider buying and selling activity for Catalent.

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CTLT stock can currently be purchased for approximately $77.47.

Catalent has a market capitalization of $12.00 billion and generates $2.52 billion in revenue each year. The company earns $137.40 million in net income (profit) each year or $1.62 on an earnings per share basis. Catalent employs 12,300 workers across the globe.

The official website for Catalent is www.catalent.com.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]